Knockdown of endogenous β-catenin levels also reduced IGF-1-insensitized TMZ cytotoxicity (Fig 1K) and DNA damage (Fig 1L), suggesting that IGF-1 reduces glioma cell sensitivity to TMZ treatment via activating the WNT/β-catenin pathway. Here, IGF1 is linked to glioma.